To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.
≥18 years old
Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma
The unresectable stage of metastatic disease has not received any systemic antitumor therapy
For subjects previously receiving neoadjuvant or adjuvant therapy, the date of first discovery of disease progression must be at least 12 months removed from the date of last administration of neoadjuvant or adjuvant therapy
Patients with known MSI-H or dMMR who were evaluated by investigators as suitable for treatment with immune checkpoint inhibitors.
Patients allergic to the investigational drug and its excipients
Underweight (body mass index [BMI]<18.5 kg/m²
Known or suspected central nervous system metastasis